vs
Apellis Pharmaceuticals, Inc.（APLS）与Enpro Inc.（NPO）财务数据对比。点击上方公司名可切换其他公司
Enpro Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.5倍（$295.4M vs $199.9M），Enpro Inc.净利率更高（-10.8% vs -29.5%，领先18.7%），Enpro Inc.同比增速更快（14.3% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 7.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Enpro是总部位于美国的工业技术企业，面向半导体、航空航天、发电、重卡、农业机械、化工处理、浆纸、生命科学等技术密集型领域设计生产专用产品及材料。公司在全球12个国家布局61个核心生产基地，下设密封技术、先进表面技术及工程技术三大业务板块。
APLS vs NPO — 直观对比
营收规模更大
NPO
是对方的1.5倍
$199.9M
营收增速更快
NPO
高出20.3%
-5.9%
净利率更高
NPO
高出18.7%
-29.5%
两年增速更快
APLS
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $295.4M |
| 净利润 | $-59.0M | $-32.0M |
| 毛利率 | — | 42.1% |
| 营业利润率 | -25.6% | 11.2% |
| 净利率 | -29.5% | -10.8% |
| 营收同比 | -5.9% | 14.3% |
| 净利润同比 | -62.2% | -330.2% |
| 每股收益（稀释后） | $-0.40 | $-1.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSNPO
| Q4 25 | $199.9M | $295.4M | ||
| Q3 25 | $458.6M | $286.6M | ||
| Q2 25 | $178.5M | $288.1M | ||
| Q1 25 | $166.8M | $273.2M | ||
| Q4 24 | $212.5M | $258.4M | ||
| Q3 24 | $196.8M | $260.9M | ||
| Q2 24 | $199.7M | $271.9M | ||
| Q1 24 | $172.3M | $257.5M |
净利润APLSNPO
| Q4 25 | $-59.0M | $-32.0M | ||
| Q3 25 | $215.7M | $21.6M | ||
| Q2 25 | $-42.2M | $26.4M | ||
| Q1 25 | $-92.2M | $24.5M | ||
| Q4 24 | $-36.4M | $13.9M | ||
| Q3 24 | $-57.4M | $19.8M | ||
| Q2 24 | $-37.7M | $26.7M | ||
| Q1 24 | $-66.4M | $12.5M |
毛利率APLSNPO
| Q4 25 | — | 42.1% | ||
| Q3 25 | — | 41.9% | ||
| Q2 25 | — | 43.3% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 42.3% | ||
| Q3 24 | — | 42.3% | ||
| Q2 24 | — | 43.8% | ||
| Q1 24 | — | 41.2% |
营业利润率APLSNPO
| Q4 25 | -25.6% | 11.2% | ||
| Q3 25 | 48.7% | 14.3% | ||
| Q2 25 | -18.6% | 15.9% | ||
| Q1 25 | -50.0% | 15.3% | ||
| Q4 24 | -12.3% | 12.5% | ||
| Q3 24 | -24.0% | 13.1% | ||
| Q2 24 | -14.7% | 17.7% | ||
| Q1 24 | -36.0% | 10.9% |
净利率APLSNPO
| Q4 25 | -29.5% | -10.8% | ||
| Q3 25 | 47.0% | 7.5% | ||
| Q2 25 | -23.6% | 9.2% | ||
| Q1 25 | -55.3% | 9.0% | ||
| Q4 24 | -17.1% | 5.4% | ||
| Q3 24 | -29.2% | 7.6% | ||
| Q2 24 | -18.9% | 9.8% | ||
| Q1 24 | -38.5% | 4.9% |
每股收益（稀释后）APLSNPO
| Q4 25 | $-0.40 | $-1.50 | ||
| Q3 25 | $1.67 | $1.01 | ||
| Q2 25 | $-0.33 | $1.25 | ||
| Q1 25 | $-0.74 | $1.15 | ||
| Q4 24 | $-0.30 | $0.65 | ||
| Q3 24 | $-0.46 | $0.94 | ||
| Q2 24 | $-0.30 | $1.27 | ||
| Q1 24 | $-0.54 | $0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $114.7M |
| 总债务越低越好 | — | $655.3M |
| 股东权益账面价值 | $370.1M | $1.5B |
| 总资产 | $1.1B | $2.7B |
| 负债/权益比越低杠杆越低 | — | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资APLSNPO
| Q4 25 | $466.2M | $114.7M | ||
| Q3 25 | $479.2M | $132.9M | ||
| Q2 25 | $370.0M | $107.1M | ||
| Q1 25 | $358.4M | $240.3M | ||
| Q4 24 | $411.3M | $236.3M | ||
| Q3 24 | $396.9M | $206.9M | ||
| Q2 24 | $360.1M | $175.9M | ||
| Q1 24 | $325.9M | $163.9M |
总债务APLSNPO
| Q4 25 | — | $655.3M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $640.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | $644.9M |
股东权益APLSNPO
| Q4 25 | $370.1M | $1.5B | ||
| Q3 25 | $401.2M | $1.5B | ||
| Q2 25 | $156.3M | $1.5B | ||
| Q1 25 | $164.2M | $1.5B | ||
| Q4 24 | $228.5M | $1.4B | ||
| Q3 24 | $237.1M | $1.5B | ||
| Q2 24 | $264.3M | $1.4B | ||
| Q1 24 | $266.7M | $1.4B |
总资产APLSNPO
| Q4 25 | $1.1B | $2.7B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $821.4M | $2.4B | ||
| Q1 25 | $807.3M | $2.5B | ||
| Q4 24 | $885.1M | $2.5B | ||
| Q3 24 | $901.9M | $2.5B | ||
| Q2 24 | $904.5M | $2.5B | ||
| Q1 24 | $831.9M | $2.5B |
负债/权益比APLSNPO
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | 4.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSNPO
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $65.3M | ||
| Q2 25 | $4.4M | $52.2M | ||
| Q1 25 | $-53.4M | $21.0M | ||
| Q4 24 | $19.4M | $59.4M | ||
| Q3 24 | $34.1M | $54.0M | ||
| Q2 24 | $-8.3M | $43.2M | ||
| Q1 24 | $-133.0M | $6.3M |
自由现金流APLSNPO
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $53.4M | ||
| Q2 25 | $4.4M | $42.3M | ||
| Q1 25 | $-53.4M | $13.0M | ||
| Q4 24 | $19.3M | $49.1M | ||
| Q3 24 | — | $48.3M | ||
| Q2 24 | $-8.4M | $38.3M | ||
| Q1 24 | $-133.3M | $-1.9M |
自由现金流率APLSNPO
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 18.6% | ||
| Q2 25 | 2.5% | 14.7% | ||
| Q1 25 | -32.0% | 4.8% | ||
| Q4 24 | 9.1% | 19.0% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | -4.2% | 14.1% | ||
| Q1 24 | -77.3% | -0.7% |
资本支出强度APLSNPO
| Q4 25 | 0.1% | 4.1% | ||
| Q3 25 | 0.0% | 4.2% | ||
| Q2 25 | 0.0% | 3.4% | ||
| Q1 25 | 0.0% | 2.9% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | 0.0% | 2.2% | ||
| Q2 24 | 0.0% | 1.8% | ||
| Q1 24 | 0.2% | 3.2% |
现金转化率APLSNPO
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 3.02× | ||
| Q2 25 | — | 1.98× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 4.27× | ||
| Q3 24 | — | 2.73× | ||
| Q2 24 | — | 1.62× | ||
| Q1 24 | — | 0.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
NPO
| Sealing Technologies Segment | $187.0M | 63% |
| General Industrial | $71.3M | 24% |
| Power Generation | $19.9M | 7% |
| Oiland Gas Market | $15.0M | 5% |
| Semiconductors | $2.2M | 1% |
